Clinical Trials · NCT07446998

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Name: Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 2Semaglutide

Phase: Phase 2
Recruitment status: Active Not Recruiting
Sponsor: Veru Inc.
Enrollment: 239
Start date: Mar 2026
Locations: 13 sites, United States
Primary endpoint: To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.

View Semaglutide compound reference